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ABSTRACT
Introduction:  Clinical research is conducted by academia, cooperative groups 
(CGs) or pharmaceutical industry. Here, we evaluate the role of CGs and funding 
sources in the development of guidelines for breast cancer therapies.
Results: We identified 94 studies. CGs were involved in 28 (30%) studies 
while industry either partially or fully sponsored 64 (68%) studies. The 
number of industry funded studies increased over time (from 0% in 1976 to 
100% in 2014; p for trend = 0.048). Only 10 (11%) government or academic 
studies were identified. Studies conducted by GCs included a greater number 
of subjects (median 448 vs. 284; p = 0.015), were more common in the neo/
adjuvant setting (p < 0.0001), and were more often randomized (p = 0.018) 
phase III (p < 0.0001) trials. Phase III trial remained significant predictor for 
CG-sponsored trials (OR 7.1 p = 0.004) in a multivariable analysis. Industry 
funding was associated with higher likelihood of positive outcomes favoring the 
sponsored experimental arm (p = 0.013) but this relationship was not seen for 
CG-sponsored trials (p = 0.53). 
Materials and Methods:  ASCO, ESMO, and NCCN guidelines were searched to 
identify systemic anti-cancer therapies for early-stage and metastatic breast cancer.  
Trial characteristics and outcomes were collected. We identified sponsors and/or the 
funding source(s) and determined whether CGs, industry, or government or academic 
institutions were involved. Chi-square tests were used for comparison between 
studies. 
Conclusions: Industry funding is present in the majority of studies providing 
the basis for which recommendations about treatment of breast cancer are 
made. Industry funding, but not CG-based funding, was associated with higher 
likelihood of positive outcomes in clinical studies supporting guidelines for 
systemic therapy.
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INTRODUCTION
Clinical trials play a crucial role for the development 
of novel therapeutic agents in oncology [1].  Once a 
compound has been identified and assessed for activity 
in preclinical models, the evaluation in clinical studies 
for safety and clinical efficacy is mandatory. Indeed, the 
approval of a new agent should be based, ideally on an 
improvement in overall survival (or its valid surrogate), 
its quality, or both. Thus, well designed clinical trials need 
to be adequately funded and promoted. Clinical research 
of systemic therapy can be sponsored through non-profit 
organizations mainly public resources (i.e. government or 
academic institutions), by pharmaceutical companies (i.e. for 
profit), or both. Although the pharmaceutical industry plays 
a key role in the discovery of novel drugs, the collaboration 
with physicians in academic institutions is essential during 
clinical evaluation [2]. Therefore, studies can be run directly 
by private companies, or be supported independently by 
cooperative groups (CGs) or academic centres.
Within recent years, conduct of oncology clinical 
trials has become increasingly complex. This may be 
explained by different factors: more demanding regulatory 
requirements, diseases of great complexity, enhanced 
standards of care and increasing costs of clinical research. 
Recently, concerns have been raised by government 
funding agencies regarding a state of crisis conducting 
cancer clinical trials, particularly those run by CGs [3].
There are no data on the influence of CGs on outcome 
of breast cancer drug therapy trials. Here, we evaluate 
the impact of the funding source and role of CGs in the 
development of drugs for the treatment of breast cancer and 
explore the association of funding with the characteristics of 
these trials. We hypothesized that characteristics, outcome 
and the reported methodological quality of drug therapy trials 
for breast cancer differ depending on the funding source.
RESULTS
Selection strategy and characteristics of studies
Figure 1 summarizes the article selection process. 
We identified 94 studies published between 1976 and 2014 
supporting 112 approved and recommended cytotoxic 
agents and targeted therapies in different breast cancer 
settings.
Characteristics of the selected studies are shown in 
Table 1. The majority of these trials were multicenter (n 
= 79, 84%), randomized (n = 71, 75%), phase III (n = 56, 
60%), performed in the metastatic setting (n = 71, 76%), 
and used intermediate end points (n = 83, 88%).
Funding sources of studies 
Cooperative Groups were involved in 28 (30%) 
studies. When evaluating industry-funded studies the 
number of studies increased to 64 studies (68%), being 
for 40 studies (42.5%) exclusively industry the funding 
source. Sixteen studies (57%) conducted by GCs were 
also funded by pharmaceutical industry. Government or 
academic studies were restricted to 10 (11%). In 9 cases 
(9%) funding source was not specified (Table 1).  The 
number of studies sponsored by industry increased over 
time (from 0% in 1976 to 6% in 1995 and 100% in 2014, 
p for trend = 0.048) (Figure 2). 
Funding source and reporting quality of trials
Characteristics of clinical trials differed significantly 
according to the funding source (Table 2). Compared to 
industry funded studies, those supported by CGs included 
a greater number of subjects (median 448 vs. 284; p = 
0.015), were more common in the neo/adjuvant setting 
(50% vs. 14%, p < 0.0001) and were more likely to be 
phase III (93% vs. 57%, p < 0.0001), randomized (93% 
vs. 70%, p = 0.018) and multicentre (100% vs. 84%, p 
= 0.027) studies. After adjusting for confounding factors, 
phase III trials remained significant predictors for CG-
sponsored trials (OR 7.1 [95% CI 1,41–35,64] p = 0.004) 
in multivariable analysis.
Association of funding source with the outcome
All RCT could be assessed for efficacy outcomes. 
Industry funding was associated with higher likelihood 
of positive outcomes supporting guideline recommended 
systemic therapy for breast cancer (61% for not industry-
sponsored vs. 88% for industry-sponsored, p = 0.013). In 
contrast, an association between CG funding and positive 
study outcome was not found (78% CG-sponsored vs. 
84% not-sponsored by CGs, p = 0.53).
DISCUSSION
In the present study we explore the role of CGs 
and academic research and the funding source of clinical 
studies supporting guidelines for systemic therapy in breast 
cancer. Of note, pharmaceutical industry involvement is 
present in the majority of clinical studies including those 
run by CGs. We observed that such funding has increased 
over time. In addition, the role of CGs has proportionally 
decreased although a presence is still observed in the 
adjuvant setting. Government or academic research is very 
limited in breast cancer.
Our article has relevant clinical implications as it 
describes the trend in clinical research in this tumor type 
and how sponsorship has changed from being largely 
academic to largely commercial. The fact that exclusively 
academic research is a limited contributor to guideline 
recommendations highlights the limitations to develop 
relevant hypotheses when they come from academic 
centers and do not have a potential commercial interest. 
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Table 1: Study characteristics
Characteristics No. (%)  94
Sample Size, median (range) 657 (7–8381)
Year of publication
 1976–2003 30 (32%)
 2004–2014 64 (68%)
Cooperative Groups
 Yes 28 (30%)
 No 57 (61%)
 Unspecified 9 (9%)
Industry funding
 Yes 64 (68%)
 No 21 (22%)
 Unspecified 9 (9%)
Type of agent
 Chemotherapy 61 (65%)
 Chemotherapy and Targeted Agents 33 (35%)
Setting
 Neo/Adjuvant 23 (24%)
 Metastatic 71 (76%)
Study design
 Randomized 71 (75%)
 Single-arm 23 (25%)
Phase of study
 II 29 (31%)
 III 56 (60%)
 Retrospective trials 2 (2%)
 No reported 7 (7%)
Blinding
 Yes 2 (2%)
 No 69 (74%)
 No applicable 23 (24%)
Primary endpoint 
 Overall survival 11 (12%)
 Intermediate endpoint 83 (88%)
Number of study centers
 Multiple 79 (84%)
 Single 15 (16%)
Number of countries of study conduct
 Multiple 49 (52%)
 Single 45 (48%)
Journal impact factors (IFs)
 Low (IF < 5.5) 11 (12%)
 Intermediate (IF 5.5–18.5) 19 (20%)
 High (IF > 18.5) 64 (68%)
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Some clinical problems are not linked with a potential 
profit and therefore are not attractive targets for industry 
funded research. In addition to this, clinical research has 
become more expensive and complex what clearly justifies 
the small number of government or academic studies. 
Conversely, public funding is not sufficient to cover all 
costs associated with independent clinical research. In this 
context, it is unknown how the decrease in independent 
research can affect the resolution of clinical problems 
observed by independent investigators. 
In this study, a positive outcome favoring the 
experimental arm was more likely for industry funded 
trials than for CGs-sponsored trials. In line with this is the 
fact that pharmaceutical industry funding and support of 
biomedical research has dramatically increased over the 
last years being now the main funding source [4, 5]. This 
has led to concerns regarding a potential source of bias 
due to a link between industry funding and an increased 
likelihood of pro-industry results and conclusions [6–8] 
although methodological quality has been shown to be 
similar in trials with industry collaboration than those 
without industry funding [9]. How to solve this problem 
is not easy, but mechanisms to decrease complexity at 
least from regulatory bodies could permit to perform less 
expensive studies that could be funded totally with public 
sources. 
Of interest, the fact that the role of CGs has 
proportionally decreased over time indirectly measures 
the influence of industry in independent research and the 
complexity to execute multinational studies. Although 
Table 2: Clinical trials characteristics according to funding source
n (%) Cooperative Groups (%)
Non-Cooperative 
Groups (%) P value
Number 85 (100%) 28 (40%) 57 (60%)
Number of study subjects
 Mean ± SD
 Median (range)
670 ± 1248
292 (22–8381)
1416 ± 2020
448 (77–8381)
384.46 ± 493.94
284 (28–3384) 0.015
Number of study centres
 Multiple
 Single
76 (89%)
9 (11%)
28 (100%)
0 (0%)
48 (84%)
9 (16%) 0.027
Number of countries of study 
conduct
 Multiple
 Single
48 (56%)
37 (44%)
12 (43%)
16 (57%)
36 (63%)
21 (37%) 0.07
Blinding
 Yes
 No
2 (%)
58 (%)
1 (5%)
19 (95%)
1 (2.5%)
39 (97.5%) 1.0
Type of design
 Randomized
 Single Arm
66 (78%)
19 (22%)
26 (93%)
2 (7%)
40 (70%)
17 (30%) 0.018
Type of study
 Phase III
 Phase II
55 (69%)
25 (31%)
25 (93%)
2 (7%)
30 (57%)
23 (43%) < 0.0001
Clinical setting
 Metastatic
 Neo/adjuvant
63 (74%)
22 (26%)
14 (50%)
14 (50%)
49 (86%)
8 (14%)
< 0.0001
Use of drug combinations
 Yes
 No
57 (67%)
28 (33%)
21 (75%)
7 (25%)
36 (63%)
21 (37%) 0.27
Primary Endpoint
 Overall Survival 
 Intermediate Endpoint
7 (8%)
78 (92%)
1 (4%)
27 (96%)
6 (10.5%)
51 (89.5%) 0.42
Journal Impact Factor (IF)
 Low (IF < 5.5)
 Intermediate (IF 5.5–18.5)
 High (IF > 18.5)
7 (8%)
16 (18%)
62 (74%)
2 (7%)
6 (21%)
20 (72%)
5 (9%)
10 (18%)
42 (73%)
0.92
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the primary focus of CGs is perform large, definitive, 
randomized phase III studies, they have also played a role 
in the development of novel therapeutic drugs in phase I 
and phase II trials [10]. However, CGs still have a role in 
areas where the inclusion of a high number of patients are 
necessary like in the adjuvant setting. As expected, our 
results show that studies conducted by GCs were more 
often phase III trials and suggesting that well-designed 
phase III RCTs can prevent bias in the comparison of 
treatments and provide a sound basis for changes in 
clinical practice [1]. In this area a large number of studies 
were sponsored by CGs with funding from pharmaceutical 
companies. 
Our study has limitations. Funding data and role 
of the sponsors was not always adequately reported. In 
our study funding data abstraction relied on subjective 
interpretations of language. To address this limitation, 
we confirmed doubtful cases with a third author. As our 
study was limited to breast cancer, it is unclear whether 
our results could be generalizable to other cancer sites. 
However, for tumors with a similar incidence the 
probability to observe similar findings is high. 
In conclusion, we evaluated the role of CGs in breast 
cancer and its funding source, identifying a substantial 
presence of those funded by the pharmaceutical industry, 
with a decrease in the proportion of those supported by 
CGs exclusively. Endorsement of experimental drugs was 
more frequent for studies with industry funding.
MATERIALS AND METHODS
Search strategy
The most recent versions of the American Society 
of Clinical Oncology (ASCO) [11], European Society 
of Medical Oncology (ESMO) [12], and National 
Comprehensive Cancer Network (NCCN) guidelines [13] 
were searched to identify chemotherapy drugs and targeted 
therapies endorsed to treat early-stage and metastatic 
breast cancer. Subsequently, we identified original articles 
published between 1976 and 2014 that supported those 
drug recommendations. When multiple (or overlapping) 
articles for the same study were identified, the most recent 
publication was included. Articles regarding genetic 
Figure 1: Flow chart showing search results.
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risk evaluation, screening, type of surgery, hormonal 
therapy, and radiotherapy were excluded. Two reviewers 
(G.A. and A.T.) independently assessed each trial for 
the funding source, study characteristics, and outcomes. 
Disagreements were resolved by a third author (AO). 
Data extraction
Data on the journal and year of publication, total 
number of study subjects, site locations (number of study 
countries and number of study centres), type of study 
drug, phase of the study (II vs. III), the design of the study 
(randomized vs. single-arm), and intervention arms were 
recorded. The 2015 journal impact factors (IFs) were 
obtained from Thomson Reuters Journal Citation Reports 
and classified as low (IF < 5.5), intermediate (IF 5.5–
18.5), or high (IF > 18.5).
Funding information and outcome assessment
We also extracted how funding sources and 
sponsorship were defined. Funding sources were classified 
as CGs, industry or government or academic organizations 
based on the recorded lead sponsor and/or collaborator 
and/or funding information reported in the disclosure in 
the published manuscript. “Lead sponsor” was defined as 
the organization responsible for overseeing the trial and 
analyzing study data, while “collaborator” was defined as an 
organization other than the sponsor that provides support for 
a clinical study, including funding, design, implementation, 
data analysis, or reporting [14]. If a CG was listed as a 
lead sponsor or as a collaborator the trial was considered 
“CG-sponsored”. If industry was the lead sponsor or was 
listed as a collaborator, the trial was classified as “industry 
sponsored”. Of the CG-sponsored trials, those with full or 
partial funding from industry were categorized as “industry 
funded”. Trials sponsored only with public funding (e.g. 
such as National Cancer Institute [NCI] and National 
Institutes of Health [NIH] or academic institutions) as 
“government or academic funded”. When no funding source 
was declared, these trials were classified as unspecified.  
A positive outcome was defined as the pre-specified 
measure of success for the primary outcome has been 
met -that is, whether a P value of less than 0.05 has been 
achieved for the difference in treatments [15]. Of note, 
randomized controlled trials (RCTs) with a statistically 
significant result favoring experimental drug for the 
primary outcome or at least one dose showing significant 
efficacy in primary outcome without increased adverse 
events, were considered as positive clinical trials. RCTs 
with a statistically significant result in favor of the 
active comparator drug over experimental drug or when 
significant safety concerns were found for primary 
outcome were considered negative clinical trials. Outcome 
could not be assessed if no study intervention arm was 
declared as experimental a priori.
Statistical analysis
Means and proportions were used to describe the 
data. Comparisons of proportions between groups were 
conducted using chi-square test. Means comparisons were 
assessed using Student’s t test or Mann-Whiteny’s U, 
as appropriate.  After categorization of the years during 
which the studies were conducted we analyzed trends 
over time using the Cochran-Armitage test. Multivariable 
analysis was conducted using binary logistic regression 
with CG as dependent variable and studied factors 
as independent and Conditional Backstep as variable 
selection method, with an inclusion criteria of 0.05 and an 
exit criteria of 0.10. All p values were two-tailed. Logistic 
regression was used to adjust for potential confounders 
when assessing the association between the funding source 
and study outcome. Data analyses were conducted using 
SPSS version 22.
Figure 2: Role of funding source among clinical studies supporting guideline recommended systemic therapy for 
breast cancer over time.
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